On December 14 local time, Novo-Nordisk A/S announced that all regulatory transaction conditions related to the acquisition of USA contract pharmaceutical manufacturer Catalent by Novo Holdings have been met, and both parties can now freely complete the Trade. Novo-Nordisk A/S expects the acquisition to be completed in the coming days.
诺和诺德收购Catalent交易已获准完成
Novo-Nordisk A/S acquisition of Catalent Trade has been approved for completion.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated